Minimal residual disease prognostic for ovarian cancer survival

Key takeaways:

Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS.

Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease.

Surgery and liquid biopsy can be used to detect minimal residual disease following frontline treatment for ovarian cancer, which could allow for earlier interventions before remission into incurable disease.

Women who had minimal residual disease (MRD) detected through second-look laparoscopy or with ctDNA testing had significantly worse PFS and OS than those who did not.

“ Ovarian cancer is a sneaky cancer,” Amir A. Jazaeri, MD, vice chair for clinical research and director of the gynecologic cancer immunotherapy program at The University of Texas MD Anderson